Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CKD-841 in Postmenopausal Females
NCT04840745Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of leuprolide in precocious puberty (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration up to 1008 hours, Area Under the Curve to last measurable concentration up to 1008 hours and 13 more. Status: unknown.
02
Drugs
leuprolide
03
Conditions
precocious puberty
Beyond the preview
Go deeper on NCT04840745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840745.